{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000401","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.467085+00:00","generated_at":"2026-06-17T13:09:29.994358+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcturus Q4 2022 net income $117.3M ($4.33/diluted share), revenue surge to $160.3M on CSL deal","bullets":["Q4 2022 revenue $160.3M vs $5.8M same quarter 2021; full-year revenue $206.0M vs $12.4M.","Recorded net income $117.3M ($4.33/diluted) for Q4 vs net loss $38.7M ($1.47 loss) prior year.","Received $200M upfront from CSL Seqirus in Dec 2022; $90M milestones invoiced in Mar 2023.","Cash $391.9M at Dec 31, 2022; repaid $17.1M to Singapore, eliminating $33.3M non-recourse debt.","ARCT-154 Phase 3 booster fully enrolled in Japan; ARCT-810 Phase 2 interim data expected later 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000401","json":"https://secwatch.observer/filing/0001193805-23-000401.json","markdown":"https://secwatch.observer/filing/0001193805-23-000401.md","text":"https://secwatch.observer/filing/0001193805-23-000401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/0001193805-23-000401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/e618402_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:09:29.994358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"805564243c1fde7c5d7d78cd659097ca077f9263","claim":"Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2022 results: revenue $206.0 million, net income approximately $9.3 million, EPS $0.35 per diluted share.","evidence_excerpt":"Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction. Operating expenses : Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31, 2022, were $193.8 million compared with $215.2 million for the year ended December 31, 2021. Research and development expenses : Research and development expenses for the three months ended December 31, 2022, were $27.0 million com","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/0001193805-23-000401-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$206.0 million"},{"label":"Net income","value":"approximately $9.3 million"},{"label":"EPS","value":"$0.35 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ef8b7419108e2e576e71d21adc21caa30cb0db52","claim":"Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2022 results: revenue $160.3 million, net income approximately $117.3 million, EPS $4.33 per diluted share.","evidence_excerpt":"For the three months ended December 31, 2022, the Company reported revenue of $160.3 million compared with $5.8 million for the three months ended December 31, 2021, and $13.4 million for the three months ended September 30, 2022. Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction. Operating expenses : Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/0001193805-23-000401-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$160.3 million"},{"label":"Net income","value":"approximately $117.3 million"},{"label":"EPS","value":"$4.33 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}